OncLive TV

Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.

Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

Sarah Sammons, MD, discusses efficacy data from a phase 2 study of pumitamig in patients with locally advanced or metastatic triple-negative breast cancer.

Toni K. Choueiri, MD, discusses data from the phase 3 LITESPARK-022 trial in ccRCC after nephrectomy.

Andrea Necchi, MD, discusses final data from the SunRISe-2 study of the gemcitabine intravesical system plus cetrelimab in MIBC.

Ravi A. Madan, MD, discusses data from a phase 2 trial of enzalutamide monotherapy in patients with biochemically recurrent prostate cancer.

Jose Mauricio Mota, MD, PhD, discusses results from the Daro-PET study, which evaluated whether short-course darolutamide increases PSMA expression in prostate cancer.

Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Stacy Loeb, MD, discusses findings from a study evaluating microplastics in prostate cancer tissue.

Vernon Sondak, MD, discusses the importance of accurately distinguishing advanced cutaneous squamous cell carcinoma from basal cell carcinoma.

Balazs Halmos, MD, MS, highlights the significance of the accelerated approval of zongertinib in HER2 TKD–mutated non–small cell lung cancer.

Richard Kim, MD, discusses how data from the phase 3 POD1UM-303 trial inform the use of retifanlimab plus chemotherapy in frontline metastatic SCAC.

Igor Makhlin, MD, discusses the evolving role of FES-PET/CT as a tool to aid in the diagnosis and management of estrogen receptor–positive breast cancer.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the importance of clinical trials in gynecologic oncology.

Ranee Mehra, MD, discusses the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

Linda T. Vahdat, MD, MBA, discusses the design of a phase 2 trial of copper depletion as a strategy to prevent metastasis in high-risk TNBC.

Tycel Phillips, MD, discusses the next steps mantle cell lymphoma research needs to take and makes suggestions for future clinical trial designs.

Mehmet Bilen, MD, discusses considerations for treatment selection in mCSPC based on data from a real-world study of apalutamide vs darolutamide.

Linda T. Vahdat, MD, MBA, discusses the scientific rationale for therapeutic copper depletion to prevent triple-negative breast cancer metastasis.

Jasleen Pannu, MBBS, discusses the importance of proactive biomarker ordering and close multidisciplinary collaboration in optimal lung cancer care.

Cynthia A. Schandl, MD, PhD, discusses the role of the pathologist in expediting biomarker-driven treatment decisions in lung cancer care.

Gurbakhash Kaur, MD, discusses the potential role of CELMoDs in the multiple myeloma treatment paradigm.

Linda T. Vahdat, MD, MBA, discusses the rationale for depleting copper levels as a form of high-risk triple-negative breast cancer management.

Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.

Alexandra Rojek, MD, discusses efforts to improve the safety and efficacy of CAR T-cell therapies in lymphoma through ongoing research.

Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.